Eli Lilly's tirzepatide, marketed under the brands Mounjaro for diabetes and Zepbound for weight management, is highly ...

Eli Lilly said in August that around 50 percent of employers had chosen to cover its weight-loss drug, Zepbound, little changed from a year earlier. Novo Nordisk said last month that about 40 million ...

WASHINGTON (AP) — For the first time, federal health officials are taking aim at telehealth companies promoting unofficial ...

Patients often don’t realize that the same procedure at different locations (even with the same insurance) can have very ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat healthily and exercise regularly. … ...

Novo Nordisk's Q2 2025 sales surge as Wegovy demand grows, driven by new obesity drug data. Click here to read an analysis of ...

Viking Therapeutics targets obesity and MASH with high-risk prospects, trial concerns, and strong funding, but lags leaders ...

Donald Trump has been ridiculed for his comments about Ozempic and how he characterized the diabetic drug. He spoke in the Oval Office with RFK Jr on Monday (23 September) and questioned the ...

The researchers found that, compared to the AGHE, the Mediterranean diet resulted in a significant decrease in waist ...

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in ...

Eli Lilly has halted a study of an experimental drug, designed to prevent obesity patients from losing too much muscle, due ...

Pharmacy benefit managers are working on a proposal to voluntarily change some business practices in an effort to avoid new ...